{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-inspection-readiness-site-and-sponsor-cro”
},
“headline”: “SOP for Inspection Readiness (Site and Sponsor/CRO)”,
“description”: “Comprehensive SOP establishing processes for inspection readiness at investigator sites and at sponsor/CRO level, aligned with ICH GCP, FDA, EMA, CDSCO, and WHO expectations. Covers pre-inspection preparation, conduct support, document retrieval, interviews, closeout, and post-inspection CAPA.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Inspection Readiness (Site and Sponsor/CRO)

Purpose

To establish standardized, regulatory-compliant processes that ensure continuous inspection readiness at investigator sites and at sponsor/CRO level. This SOP defines proactive measures for maintaining the Trial Master File (TMF) and Investigator Site File (ISF), preparing personnel, coordinating vendor support, staging records for rapid retrieval, and executing structured responses before, during, and after regulatory inspections by agencies such as CDSCO, US FDA, EMA, MHRA, PMDA, and WHO-prequalification programs.

Scope

This SOP applies to all clinical trials sponsored, managed, or monitored by the organization. It encompasses site and sponsor/CRO functions including Clinical Operations, Data Management, Pharmacovigilance, Biostatistics, Medical Affairs, Regulatory Affairs, Quality Assurance (QA), and validated computerized systems (eTMF, EDC, safety databases, CTMS). It covers routine preparedness, announced/unannounced inspections, for-cause inspections, and follow-up actions.

Responsibilities

• Sponsor/CRO QA: Owns inspection readiness framework, conducts mock inspections, leads inspector interface and note-taking, coordinates responses and CAPA.
• Clinical Operations: Ensures study conduct aligns with protocol/GCP; prepares staff rosters, interview readiness, and document retrieval.
• Principal Investigator (PI): Ensures site compliance, ISF completeness, facility readiness, and availability of source documents and staff.
• Study Coordinator: Maintains screening/enrolment logs, consent files, IP accountability, and supports real-time queries from inspectors.
• Data Management/Stats: Provides data listings, audit trails, data flow diagrams, and supports database-related queries.
• Pharmacovigilance: Ensures SAE/SUSAR reporting evidence, case narratives, and regulatory submissions are retrievable.
• Regulatory Affairs: Provides submissions/approvals/notifications history and correspondence with authorities/ECs.
• IT/Systems Owner: Ensures validated access to eSystems, controlled read-only inspector accounts if applicable, and rapid report generation.

Accountability

Head of QA is accountable for overall inspection readiness and for the effectiveness of the program. The PI is accountable for site-level readiness. Departmental heads are accountable for ensuring their teams comply with this SOP and are inspection-ready at all times.

Procedure

1. Establish Continuous Readiness
1.1 Maintain a current Inspection Readiness Plan (IRP) per study, identifying functions, owners, and timelines.
1.2 Ensure TMF/eTMF and ISF/eISF are contemporaneous, complete, indexed, and audit-ready; perform monthly quality checks with documented metrics (completeness, timeliness, quality).
1.3 Maintain a live Training Matrix mapping each role to protocol- and GCP-specific training; keep certificates and CVs updated and filed.
1.4 Confirm all computerized systems are validated, with access controls, SOPs, and audit trails; keep validation summaries and user access logs ready for review.

2. Pre-Inspection Notification & Triage
2.1 Upon receiving inspection intimation (email/letter/phone) or unannounced arrival, inform QA immediately and trigger the IRP.
2.2 Designate an Inspection Lead (QA), Backroom Lead (document control), and Frontroom Coordinator (inspector-facing room manager).
2.3 Create an inspection schedule outlining opening meeting, interviews, document reviews, facility tour, and daily debriefs.
2.4 Circulate a “Do’s & Don’ts” briefing to staff (answer concisely, be truthful, refer to documents, avoid speculation).
2.5 Prepare an Inspector Information Pack: facility map, org chart, study list, role matrix, key contact sheet, and site emergency procedures.

3. Frontroom/Backroom Setup
3.1 Frontroom: Allocate a quiet, secure inspection room with network-disabled printer (if required), controlled Wi-Fi/access, and read-only eSystem accounts per policy.
3.2 Backroom: Stage a secure area where document retrieval, SME coordination, and internal discussions occur; no inspectors allowed.
3.3 Assign a Runner to shuttle documents between backroom and frontroom, ensuring version control and a Document Request Log (Annexure-1) is maintained.
3.4 Prepare Redaction SOP for PHI/PII where applicable, ensuring redactions are validated and traceable.

4. Document Retrieval & Control
4.1 Log each inspector request (time, requester, exact description, owner, due time) in the Document Request Log; prioritize safety and informed consent items.
4.2 Retrieve documents from TMF/ISF or eSystems; verify they are the controlled/current versions before release.
4.3 Stamp or watermark “INSPECTOR COPY” where policy permits; avoid releasing originals unless required by law and receipted.
4.4 Record every handover/return; reconcile at day-end to ensure no documents are missing.

5. Interviews & SME Management
5.1 Schedule interviews with PI, sub-investigators, coordinators, CRAs, DM/Stats, PV, Regulatory, and IT as requested.
5.2 Conduct quick pre-briefs reminding SMEs to answer what is asked, cite SOPs/protocol sections, and demonstrate records.
5.3 During interviews, assign a Notetaker to record questions, verbatim responses, and referenced documents (Annexure-2 Interview Log).
5.4 If unsure of an answer, commit to revert with documentation; route the query to backroom for preparation.

6. Daily Huddles & Issue Escalation
6.1 Hold a daily internal huddle to review open requests, potential gaps, and corrective steps.
6.2 Use an Issues Log (Annexure-3) to track potential observations (consent deficiencies, IP reconciliation gaps, late SAE reporting, missing training).
6.3 Implement immediate corrections where permissible (e.g., file missing documents, update delegation log) and document the action and rationale.

7. Data Integrity & System Demonstrations
7.1 Prepare system “walkthroughs” showing data flow, audit trail examples, user access controls, backup/DR, and CSV evidence.
7.2 Demonstrate ALCOA+ principles with examples (attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, available).
7.3 Provide KRI/QTL dashboards and monitoring evidence supporting risk-based oversight when requested.

8. Closing Meeting Preparation
8.1 Prior to closeout, internally reconcile all requests and responses; ensure no outstanding handovers.
8.2 Prepare factual clarifications with references; avoid debate—seek to ensure mutual understanding.
8.3 Record verbal observations discussed and anticipated classifications where disclosed by inspectors.

9. Post-Inspection Response & CAPA
9.1 On receipt of the formal observation letter (e.g., FDA Form 483, EMA/MHRA letter, CDSCO memo), log it and initiate CAPA within mandated timelines.
9.2 Perform root cause analysis (e.g., 5-Whys, Fishbone) for each observation; define corrective and preventive actions with owners and due dates.
9.3 Submit written responses per agency-specified format and timeline (typically 15 business days for FDA Form 483).
9.4 Track CAPA to closure, verify effectiveness (spot checks, audits), and file evidence in TMF/ISF and QMS (Annexure-4 CAPA Tracker).
9.5 Conduct a lessons-learned session; update SOPs, work instructions, and training as required.

10. Ongoing Readiness & Mock Inspections
10.1 Schedule risk-based mock inspections at sites and sponsor/CRO at least annually or before pivotal milestones.
10.2 Document mock outcomes, generate CAPA, and verify completion prior to regulatory milestones (e.g., DBL, submission).
10.3 Trend common gaps (consent errors, IP accountability, PV timelines) and implement systemic preventive actions.

Abbreviations

• SOP: Standard Operating Procedure
• PI: Principal Investigator
• TMF/ISF: Trial Master File / Investigator Site File
• EDC/CTMS: Electronic Data Capture / Clinical Trial Management System
• PV: Pharmacovigilance
• KRI/QTL: Key Risk Indicator / Quality Tolerance Limit
• ALCOA+: Attributable, Legible, Contemporaneous, Original, Accurate (+ Complete, Consistent, Enduring, Available)
• CSV: Computerized System Validation
• IRP: Inspection Readiness Plan

Documents

1. Document Request Log (Annexure-1)
2. Interview Log (Annexure-2)
3. Inspection Issues Log (Annexure-3)
4. Post-Inspection CAPA Tracker (Annexure-4)

References

• ICH E6(R2/R3) – Good Clinical Practice
• US FDA – Bioresearch Monitoring Program (BIMO) Inspections
• EMA – GCP Inspections and Guidance
• CDSCO – Clinical Trial Inspections
• WHO – Inspection Readiness and Quality Systems

Version: 1.0

Approval Section

Annexures

Annexure-1: Document Request Log

Annexure-2: Interview Log

Annexure-3: Inspection Issues Log

Annexure-4: Post-Inspection CAPA Tracker

Revision History

For more SOPs visit: Pharma SOP